2016
DOI: 10.1093/brain/aww330
|View full text |Cite
|
Sign up to set email alerts
|

Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice

Abstract: CitationInterleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. 2017, 140 Research, 2017, Vol. 45, No. 5 Published online 28 November 201628 November doi: 10.1093 ABSTRACTCentrosomal 190 kDa protein (CP190) is a promoter binding factor, mediates long-range interactions in the context of enhancer-promoter contacts and in chromosomal domain formation. All Drosophila insulator proteins bind CP190 suggesting a crucial role in insulator function. CP190 has major e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
109
3

Year Published

2017
2017
2022
2022

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 112 publications
(126 citation statements)
references
References 102 publications
8
109
3
Order By: Relevance
“…It is likely that additional genes play a role, either independently or via an interaction with Trpc3, in determining severity of AD neuropathology. This idea is supported by the fact that positional candidates Fgf2 and Il2 have independently been associated with amyloid levels in model systems (Alves et al, 2017;Katsouri et al, 2015). In addition, the QTL identified in our AD-BXD panel does not overlap with those broad regions associated with pathology previously (Ryman et al, 2008;Sebastiani et al, 2006).…”
Section: Trpc3 As a Novel Modulator Of Ad Resiliencesupporting
confidence: 59%
See 1 more Smart Citation
“…It is likely that additional genes play a role, either independently or via an interaction with Trpc3, in determining severity of AD neuropathology. This idea is supported by the fact that positional candidates Fgf2 and Il2 have independently been associated with amyloid levels in model systems (Alves et al, 2017;Katsouri et al, 2015). In addition, the QTL identified in our AD-BXD panel does not overlap with those broad regions associated with pathology previously (Ryman et al, 2008;Sebastiani et al, 2006).…”
Section: Trpc3 As a Novel Modulator Of Ad Resiliencesupporting
confidence: 59%
“…Three of these six genes, fibroblast growth factor 2 (Fgf2) (Donnini et al, 2006;Katsouri et al, 2015), cyclin A2 (Ccna2) (Chandrasekaran and Bonchev, 2016), and interleukin 2 (Il2) (Alves et al, 2017) have previously been associated with Aβ levels, suggesting variants in one or multiple genes in this region may influence amyloid load. Of the remaining 3 genes that had not been previously implicated as involved in amyloid accumulation, Trpc3 emerged as the gene with the most biological evidence for a potential functional role in AD.…”
Section: Ad-bxd Panel Exhibits Heritable Variation In Amyloid Patholomentioning
confidence: 99%
“…[30, 32] In neurons, IL-2 was shown to restore T-cell function and alleviate AD symptoms including the loss of synaptic plasticity and memory. [42] Thus, when Src and/or p52shc are away from the membrane, it appears to offer protective effects against disease-associated molecular events.…”
Section: Intracellular Ca+2 Concentration Coordinates the Durationmentioning
confidence: 99%
“…Systemic transfer of both standard CD4 + CD25 + cells, or CD4 + CD25 + cells following education with human umbilical cord mesenchymal stem cells, which increases their suppressive capacity, reduces Aβ plaque deposition and improves cognitive function in 3xTg and AβPPswe/PS1dE9 double‐transgenic mice, respectively (Baek et al, ; Yang, Yang, Xie, Wei, & Bi, ). Further, peripheral IL‐2 therapy, which stimulates Treg cell proliferation, has been shown to activate and expand Treg cell populations systemically and in the brain, induce astrocyte recruitment and activation around amyloid plaques in the hippocampus, increase plaque‐associated microglia, improve synaptic plasticity, reduce spine density, and restore cognitive function in animal models of Alzheimer's disease (Alves et al, ; Dansokho et al, ).…”
Section: Treg Cells In Neurodegenerative Diseasesmentioning
confidence: 99%